The receptor tyrosine kinase (RTK) ALK is mutated in NB tumors and in the germline of patients with familial NB [14–16], and ALK plays a major role in the signal transduction mechanism driving NB development, being a major potential target in NB targeted therapy [17, 18]. Here, NTRK1 is linked to neuroblastoma.